We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect — and ...

Gilead Sciences, the maker of a twice-a year anti-HIV injection, has approached South Africa’s medicine regulator to discuss how to get the shot registered locally as fast as possible in the country.

In today’s newsletter, Mia Malan tells us why the US isn’t giving SA LEN. Sign up for our newsletter today. By shutting South Africa out of its overseas funding for the roll-out of the revolutionary ...

In today’s newsletter, Linda Pretorius asks “who should get what slice of the LEN pie”? Sign up for our newsletter today. What’s the best way to divvy up a shipment of medicine that will cover less ...

In today’s newsletter, Tanya Pampalone explains the NHI’s policy paradox. Sign up for our newsletter today. One of the soldiers in the small army recently spat his message along the busy corridor that ...

In today’s newsletter, Mia Malan explains how Sahpra registered LEN within 65 days, how it works and how it will get distributed. Sign up for our newsletter today. South Africa has become the first ...

Although taxpayer money now funds the bulk of South Africa’s HIV programme, getting to the point where we have the largest HIV treatment programme in the world, would not have been possible without ...

In today’s newsletter, Mia Malan asks who in SA should get LEN first. Sign up for our newsletter today. One in ten clinics in South Africa — across 22 health districts in six provinces — could start ...

In July 2025, several South African news outlets resurfaced a 2020 report that looked at whether common HIV medications, known as antiretrovirals or ARVs, were present in local water sources and what ...

In today’s newsletter, Zano Kunene introduces us to influencers who help prop up Big Tobacco. Sign up for our newsletter today. Usually South African influencer Honour Zuma, known as Cyan Boujee, ...

In today’s newsletter, Mia Malan tells us more about how SA will roll out LEN. Sign up for our newsletter today. The health department plans to make the twice-a-year anti-HIV jab, lenacapavir, ...